Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Nov 14, 2017
Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three months ended September 30, 2017.  Recent Corporate...

Oct 30, 2017
Mateon Therapeutics Announces Updated Data from Fifth Cohort of Phase 1b Study of OXi4503 in Acute Myeloid Leukemia

New Data Continue to Show OXi4503 has Significant Potential as New Treatment for AMLOXi4503 Recently Prioritized as Lead Drug Development Program at Mateon SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...

Sep 26, 2017
Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML

Company to terminate FOCUS study due to lack of clear efficacy signal in the third interim analysisCompany to reduce headcount, concentrate on OXi4503 for acute myeloid leukemia (AML) SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting...

Sep 6, 2017
Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. Ma...

Aug 16, 2017
Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer

Primary Endpoint - Early Progression Free Survival data favors CA4PCA4P continues to be safe and well-toleratedNext interim analysis expected in September SOUTH SAN FRANCISCO, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatmen...

Aug 2, 2017
Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three months ended June 30, 2017.  Recent Co...

Aug 1, 2017
Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer

Recruitment rate significantly increased following initial positive interim analysisInterim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH SAN FRANCISCO, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disr...

Jul 31, 2017
Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML

Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observed SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced preliminary ...

Jun 28, 2017
Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors

CA4P in combination with anti-CTLA-4 antibodies resulted in 77% reduction in tumor size compared to anti-CTLA-4 antibodies alone and 89% reduction compared to controlSurvival benefit observed for animals receiving combination therapy SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharm...

Jun 12, 2017
Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones

Interim Analyses for Key FOCUS Study Expected in August 2017 and September 2017Investigator-Sponsor Pauses Enrollment in PAZOFOS Study in U.K. SOUTH SAN FRANCISCO, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan...

1
...
NextLast
= add release to Briefcase